Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (N.C.C., J.I.W.).
Department of Medicine (N.C.C., J.I.W.), McMaster University, Hamilton, Ontario, Canada.
Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):1755-1763. doi: 10.1161/ATVBAHA.123.318781. Epub 2023 Aug 31.
FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous thromboembolism. In this review, we discuss the role of FXI and FXII in the pathogenesis of venous thromboembolism, explain why FXI is a better target, and explain why FXI inhibitors have potential advantages over currently available anticoagulants. Finally, we describe the FXI inhibitors under development and discuss their potential to address unmet needs in venous thromboembolism management.
FXI（因子 XI）和 FXII（因子 XII）已成为新型抗凝剂的靶点，这些抗凝剂在预防和治疗静脉血栓栓塞症方面的疗效可能优于目前可用的直接口服抗凝剂，且安全性更高。在这篇综述中，我们讨论了 FXI 和 FXII 在静脉血栓栓塞症发病机制中的作用，解释了为什么 FXI 是一个更好的靶点，以及为什么 FXI 抑制剂相对于目前可用的抗凝剂具有潜在优势。最后，我们描述了正在开发的 FXI 抑制剂，并讨论了它们在满足静脉血栓栓塞症管理方面未满足需求方面的潜力。
